All Stories

  1. Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer’s Disease Continuum: A Retrospective Observational Study

    Article • Journal of Alzheimer’s Disease, January 2024, IOS Press

    Dr Alessandro Martorana

  2. Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients

    Article • Current Alzheimer Research, May 2018, Bentham Science Publishers

    Dr Giulia M Sancesario, Dr Alessandro Martorana, Andrea Cerri

  3. Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers

    Article • CNS & Neurological Disorders - Drug Targets, July 2017, Bentham Science Publishers

    Dr Alessandro Martorana

  4. Insulin and the Future Treatment of Alzheimer's Disease

    Article • CNS & Neurological Disorders - Drug Targets, July 2016, Bentham Science Publishers

    Dr Alessandro Martorana

  5. Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer's Dementia. Focus on Non Neuronal Participants to Neurodegeneration)

    Article • CNS & Neurological Disorders - Drug Targets, July 2016, Bentham Science Publishers

    Dr Alessandro Martorana

  6. Long-term potentiation-like cortical plasticity is disrupted in Alzheimer's disease patients independently from age of onset

    Article • Annals of Neurology, July 2016, Wiley

    Dr Alessandro Martorana

  7. Comparison between Early-Onset and Late-Onset Alzheimer's Disease Patients with Amnestic Presentation: CSF and 18F-FDG PET Study

    Article • Dementia and Geriatric Cognitive Disorders Extra, April 2016, Karger Publishers

    Dr Alessandro Martorana

  8. Reversal of LTP-Like Cortical Plasticity in Alzheimer’s Disease Patients with Tau-Related Faster Clinical Progression

    Article • Journal of Alzheimer’s Disease, January 2016, IOS Press

    Dr Alessandro Martorana, Prf Miguel Fernandez-del-Olmo

  9. Cerebrospinal Fluid Aβ42Levels: When Physiological Become Pathological State

    Article • CNS Neuroscience & Therapeutics, November 2015, Wiley

    Dr Alessandro Martorana

  10. CSF biomarkers reveal heterogeneous synaptic transmission in subgroups of Alzheimer’s disease patients

    Article • Brain Stimulation, March 2015, Elsevier

    Dr Alessandro Martorana

  11. Functional correlates of t-Tau, p-Tau and Aβ1–42 amyloid cerebrospinal fluid levels in Alzheimer’s disease

    Article • Nuclear Medicine Communications, February 2015, Wolters Kluwer Health

    Dr Alessandro Martorana

  12. 115. D2 agonist administration restores altered cortical plasticity in Alzheimer’s disease patients

    Article • Clinical Neurophysiology, January 2015, Elsevier

    Dr Alessandro Martorana

  13. 107. CSF levels of tau protein are related to detrimental SLAI and LTP-like cortical plasticity in AD patients

    Article • Clinical Neurophysiology, January 2015, Elsevier

    Dr Alessandro Martorana

  14. Cortico-Subcortical Metabolic Changes in Aging Brain: A 18F FDG PET/CT Study

    Article • International Journal of Nuclear Medicine Research, October 2014, Cosmos Scholars Publishing House

    Dr Alessandro Martorana

  15. “Is dopamine involved in Alzheimer's disease?”

    Article • Frontiers in Aging Neuroscience, September 2014, Frontiers

    Dr Alessandro Martorana

  16. Homotaurine Induces Measurable Changes of Short Latency Afferent Inhibition in a Group of Mild Cognitive Impairment Individuals

    Article • Frontiers in Aging Neuroscience, September 2014, Frontiers

    Dr Alessandro Martorana

  17. Dopaminergic Modulation of Cortical Plasticity in Alzheimer’s Disease Patients

    Article • Neuropsychopharmacology, May 2014, Springer Science + Business Media

    Dr Alessandro Martorana

  18. D2 agonist administration restores altered cortical plasticity in Alzheimer's disease patients

    Article • Neurobiology of Aging, March 2014, Elsevier

    Dr Alessandro Martorana

  19. 139. D2 agonist administration restores impaired LTP-like cortical plasticity in AD patients

    Article • Clinical Neurophysiology, November 2013, Elsevier

    Dr Alessandro Martorana

  20. P 159. D2 agonist administration restores impaired LTP-like cortical plasticity in AD patients

    Article • Clinical Neurophysiology, October 2013, Elsevier

    Dr Alessandro Martorana

  21. Frailty Among Alzheimer’s Disease Patients

    Article • CNS & Neurological Disorders - Drug Targets, June 2013, Bentham Science Publishers

    Dr Alessandro Martorana

  22. Dopamine D2-agonist Rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients

    Article • Neuropharmacology, January 2013, Elsevier

    Dr Alessandro Martorana

  23. Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients

    Article • Frontiers in Aging Neuroscience, January 2013, Frontiers

    Dr Alessandro Martorana

  24. Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer’s disease patients

    Article • Acta Neurovegetativa, March 2012, Springer Science + Business Media

    Dr Alessandro Martorana

  25. Clinical Profile of Alzheimer’s Disease Non-Responder Patient

    Article • December 2011, IntechOpen

    Dr Alessandro Martorana

  26. Altered dopamine modulation of LTD-like plasticity in Alzheimer’s disease patients

    Article • Clinical Neurophysiology, April 2011, Elsevier

    Dr Alessandro Martorana

  27. Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?

    Article • CNS Neuroscience & Therapeutics, June 2010, Wiley

    Dr Alessandro Martorana

  28. Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients

    Article • Neuropsychopharmacology, June 2009, Nature

    Dr Alessandro Martorana

  29. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

    Article • Journal of the Neurological Sciences, October 2005, Elsevier

    Dr Alessandro Martorana